Supplementary Table 4.
Cox’s regression model for multivariate analysis of the survival time of patients with CTEPH
| Factors | Exp(B) | 95% CI for Exp(B) | P |
|---|---|---|---|
| Age (years) | 1.597 | 0.914–2.790 | 0.100 |
| Gender | 1.805 | 0.991–3.286 | 0.053 |
| Treatment | 0.461 | ||
| Treatment (1) | 1.209 | 0.547–2.673 | 0.639 |
| Treatment (2) | 0.737 | 0.298–1.823 | 0.509 |
| Treatment (3) | 2.279 | 0.211–24.656 | 0.498 |
| Group | 0.207 | 0.028–1.541 | 0.124 |
| 6MWD | 1.049 | 0.521–2.111 | 0.894 |
| WHO-FC | <0.001 | ||
| WHO-FC (1)* | 0.126 | 0.049–0.319 | <0.001 |
| WHO-FC (2)* | 0.182 | 0.074–0.445 | <0.001 |
| mPAP | 0.540 | ||
| mPAP (1) | 0.460 | 0.061–3.470 | 0.452 |
| mPAP (2) | 1.266 | 0.675–2.375 | 0.463 |
*The difference is significant at the 0.05 level. Treatment, 1: Basic treatment, 2: Basic treatment + targeted drugs treatment, 3: Basic treatment + CCB treatment, WHO-FC, 1: WHO-FC I–II, 2: WHO-FC III, mPAP, 1: 26≤ mPAP ≤35, 2: 36≤ mPAP ≤45. The analysis revealed that WHO-FC was the strongest factor affecting survival time of patients with CTEPH, with the risk of death in patients with WHO FC I–II significantly lower than that in patients with WHO-FC III or IV, P < 0.001. 6MWD: 6-min walking distance; CTEPH: Chronic thromboembolic pulmonary hypertension; mPAP: Mean pulmonary arterial pressure; WHO-FC: World Health Organization functional class; RR: Relative risk; CI: Confidence interval; PEA: Pulmonary endarterectomy; CCB: Calcium channel blocker.